News Daily News FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes Shelley Wood December 02, 2016
News Daily News PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk Michael O'Riordan December 01, 2016
News Daily News Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes Michael O'Riordan December 01, 2016
News Daily News Pokémon Go Forth: Cardiologists, AHA Support Use of Augmented Reality Games That Encourage Movement Yael L. Maxwell July 22, 2016
News Daily News FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin Michael O'Riordan June 30, 2016
News Daily News Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow Caitlin E. Cox June 30, 2016
News Daily News Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina Michael O'Riordan June 30, 2016
News Industry News U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin) January 24, 2016
News Daily News Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns Todd Neale January 18, 2016
News Daily News La Actualización de las Directrices sobre la Dieta Cambia el Centro de Atención a Patrones Alimenticios Saludables Todd Neale January 18, 2016
News Daily News Sweet Surrender? Trimming Sweetness from Sugary Drinks May Cut Obesity-Related Diseases Todd Neale January 06, 2016
News Industry News Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments January 03, 2016
News Daily News Sugary Drinks an Increasing Threat to Global Cardiometabolic Health Todd Neale December 02, 2015
News Daily News Las Bebidas Azucaradas son una Amenaza contra la Salud Cardiometabólica Global Todd Neale December 02, 2015
News Industry News New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology August 20, 2015
News Industry News Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events August 20, 2015
News Industry News Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions June 05, 2015